The US Bankruptcy Court gave an order approving the bidding procedures relating to the sale of the substantially all the assets of Argos Therapeutics, Inc. on December 20, 2018. The Court approved the asset purchase agreement between the debtor and Cellscript, LLC and Immune and Cell Therapies, LLC, the stalking horse bidder, for the sale of substantially all its assets for a purchase price of $3.82 million. To qualify as a qualified bidder, interested parties should submit their bids by January 16, 2019. The initial minimum overbid should be at least $0.13 million more than the initial purchase price. The debtor has scheduled an auction on January 22, 2019. At the auction, the subsequent bids would be in increments of $0.1 million. The stalking horse bidder would be entitled to a break-up fee of $0.08 million and expense reimbursement of $0.08 million in case of termination of the asset purchase agreement. The sale hearing is scheduled for January 23, 2019.